Andrey V. Zolotarev
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Andrey V. Zolotarev has a total of 50 co-authors. Here are the top co-authors by number of shared publications:
- Elena V. Karlova
Samara State Medical University; Samara Regional Clinical Ophthalmological Hospital named after T.I. Eroshevsky
8 shared publications - Vladimir M. Malov
Samara State Medical University
4 shared publications - Elena B. Eroshevskaya
Samara State Medical University
3 shared publications - Evgeniy Zamytskiy
Samara State Medical University
3 shared publications - Ilya S. Kazakov
Samara Regional Clinical Ophthalmological Hospital named after T.I. Eroshevsky
3 shared publications - Mikhail A. Artemov
Samara Regional Clinical Ophthalmological Hospital named after T.I. Eroshevsky
3 shared publications
Latest Publications
- Open Access
- 17 November 2026
- Published by FSBEI of Higher Education SamSMU of Ministry of Health of the Russian Federation in Aspirantskiy Vestnik Povolzhiya
Drug delivery methods to the suprachoroidal space
This article provides a literature review of methods for delivering drugs to the suprachoroidal space (SСS), highlighting their challenges and adverse effects. Ophthalmologists consider the space between the choroid and sclera as a promising route for transporting pharmacological agents to the pathologically altered tissues of the choroid and retina, as drugs administered to the SСS are in direct contact with these structures of the eye, creating favorable conditions for the concentration of drugs directly at the site of the lesion. The article presents compelling evidence of positive outcomes in the treatment of retinal and uveal tract diseases. Various methods and devices have been proposed for delivering drugs to the SCS. The article discusses their advantages, limitations, and clinical significance. Despite its apparent clinical potential, suprachoroidal drug delivery is currently not widely used, largely due to the lack of a convenient, simple, predictable, and cost-effective method for administering drugs to the SCS. This highlights the need for searching of optimal approaches in this area.
- 17 November 2026
- Published by FSBEI of Higher Education SamSMU of Ministry of Health of the Russian Federation in Aspirantskiy Vestnik Povolzhiya
Open AccessDrug delivery methods to the suprachoroidal space
This article provides a literature review of methods for delivering drugs to the suprachoroidal space (SСS), highlighting their challenges and adverse effects. Ophthalmologists consider the space between the choroid and sclera as a promising route for transporting pharmacological agents to the pathologically altered tissues of the choroid and retina, as drugs administered to the SСS are in direct contact with these structures of the eye, creating favorable conditions for the concentration of drugs directly at the site of the lesion. The article presents compelling evidence of positive outcomes in the treatment of retinal and uveal tract diseases. Various methods and devices have been proposed for delivering drugs to the SCS. The article discusses their advantages, limitations, and clinical significance. Despite its apparent clinical potential, suprachoroidal drug delivery is currently not widely used, largely due to the lack of a convenient, simple, predictable, and cost-effective method for administering drugs to the SCS. This highlights the need for searching of optimal approaches in this area.
- 1 October 2026
- Published by Springer Nature
- p. 471-480
Automatic System to Determine Indications for 2RT Treatment
- 1 October 2026
- Published by Springer Nature
- p. 471-480
Automatic System to Determine Indications for 2RT Treatment
- 30 June 2026
- Published by ECO-Vector LLC (Publications) in Ophthalmology Reports
- Vol. 19 (2) , 83-93
Prospects and therapeutic strategies in the management of dry eye disease: a review
Dry eye disease (DED) is a widespread multifactorial disease, which makes the search for new effective therapies highly relevant. The novelty of this review lies in the comprehensive examination of the pathogenesis of DED and the substantiation of a promising treatment direction using corneal extracellular matrix biomimetics. The analysis showed that modern therapy of DED is not limited to simple lubrication and should be aimed at restoring ocular surface homeostasis and breaking the vicious cycle of chronic inflammation. Furthermore, it was found that multi-component preparations based on extracellular matrix biomimetics, in particular SFERO® Oko (BIOMIR Service JSC, Russia), demonstrate high efficacy in stimulating corneal regeneration and are promising for inclusion in therapeutic regimens for dry eye disease. Special attention is paid to drugs approved by the U.S. Food and Drug Administration, including cyclosporine; Xiidra® (lifitegrast 5%, Bausch Lomb Inc., USA)[℘]; Eysuvis® (loteprednol etabonate 0.25%, Kala Pharmaceuticals, USA)[℘]; Miebo® (perfluorohexyloctane, Novaliq, Germany)[℘]; and Tyrvaya® (varenicline nasal spray, Oyster Point Pharma Inc., USA)[℘]. This scientific review is based on an analysis of Russian and international sources from 2015 to 2025 and is intended for practicing ophthalmologists seeking a personalized approach to dry eye disease treatment. [℘] A drug is not registered in the Russian Federation.
- 30 June 2026
- Published by ECO-Vector LLC (Publications) in Ophthalmology Reports
- Vol. 19 (2) , 83-93
Prospects and therapeutic strategies in the management of dry eye disease: a review
Dry eye disease (DED) is a widespread multifactorial disease, which makes the search for new effective therapies highly relevant. The novelty of this review lies in the comprehensive examination of the pathogenesis of DED and the substantiation of a promising treatment direction using corneal extracellular matrix biomimetics. The analysis showed that modern therapy of DED is not limited to simple lubrication and should be aimed at restoring ocular surface homeostasis and breaking the vicious cycle of chronic inflammation. Furthermore, it was found that multi-component preparations based on extracellular matrix biomimetics, in particular SFERO® Oko (BIOMIR Service JSC, Russia), demonstrate high efficacy in stimulating corneal regeneration and are promising for inclusion in therapeutic regimens for dry eye disease. Special attention is paid to drugs approved by the U.S. Food and Drug Administration, including cyclosporine; Xiidra® (lifitegrast 5%, Bausch Lomb Inc., USA)[℘]; Eysuvis® (loteprednol etabonate 0.25%, Kala Pharmaceuticals, USA)[℘]; Miebo® (perfluorohexyloctane, Novaliq, Germany)[℘]; and Tyrvaya® (varenicline nasal spray, Oyster Point Pharma Inc., USA)[℘]. This scientific review is based on an analysis of Russian and international sources from 2015 to 2025 and is intended for practicing ophthalmologists seeking a personalized approach to dry eye disease treatment. [℘] A drug is not registered in the Russian Federation.
- 8 September 2025
- Published by Media Sphere Publishing Group in Russian Annals of Ophthalmology
- Vol. 141 (4) , 60-65
Nanosecond retinal laser therapy: three years of practical experience
Objective. This study evaluated the outcomes of a 36-month follow-up after treatment with the ELLEX 2RT nanosecond laser. Material and methods. The study included 72 patients divided into two groups. Group 1 received 2RT nanosecond laser therapy, while group 2 did not undergo laser treatment. Patients with early and intermediate stages of age-related macular degeneration (AMD) were enrolled. The exclusion criteria from the study were the presence of reticular pseudodrusen, drusenoid detachment (avascular pigment epithelial detachment) measuring >1000 μm, and areas of retinal pigment epithelium (RPE) atrophy detected by optical coherence tomography (OCT). Results. After treatment, visual acuity in group 1 did not change and remained stable at 0.99, while in group 2 there was a decrease in mean uncorrected visual acuity (UCVA) from 0.98 to 0.86. In addition, OCT findings in group 1 showed no progression in 96% (41 eyes) of cases. At the same time, in 2% (1 eye) of cases, there was a significant positive trend in relation to retinal anatomy according to OCT, and in 2% (1 eye) of cases, despite some negative dynamics in retinal anatomy, there was no decrease in vision. In contrast, the disease progressed to the wet form in 19% of group 2 patients after 36 months of follow-up. According to microperimetry, retinal sensitivity in the macular area and in 2RT foci in group 1 was stable or slightly improved. There was a trend toward improved fixation on microperimetry. Conclusion. Results of the study show that after 2RT therapy the condition of the retina can stabilize or even improve, supporting the broader use of retinal laser stimulation using a nanosecond laser in patients with early forms of AMD to prevent the progression of the disease and its transition to the wet form.
- 8 September 2025
- Published by Media Sphere Publishing Group in Russian Annals of Ophthalmology
- Vol. 141 (4) , 60-65
Nanosecond retinal laser therapy: three years of practical experience
Objective. This study evaluated the outcomes of a 36-month follow-up after treatment with the ELLEX 2RT nanosecond laser. Material and methods. The study included 72 patients divided into two groups. Group 1 received 2RT nanosecond laser therapy, while group 2 did not undergo laser treatment. Patients with early and intermediate stages of age-related macular degeneration (AMD) were enrolled. The exclusion criteria from the study were the presence of reticular pseudodrusen, drusenoid detachment (avascular pigment epithelial detachment) measuring >1000 μm, and areas of retinal pigment epithelium (RPE) atrophy detected by optical coherence tomography (OCT). Results. After treatment, visual acuity in group 1 did not change and remained stable at 0.99, while in group 2 there was a decrease in mean uncorrected visual acuity (UCVA) from 0.98 to 0.86. In addition, OCT findings in group 1 showed no progression in 96% (41 eyes) of cases. At the same time, in 2% (1 eye) of cases, there was a significant positive trend in relation to retinal anatomy according to OCT, and in 2% (1 eye) of cases, despite some negative dynamics in retinal anatomy, there was no decrease in vision. In contrast, the disease progressed to the wet form in 19% of group 2 patients after 36 months of follow-up. According to microperimetry, retinal sensitivity in the macular area and in 2RT foci in group 1 was stable or slightly improved. There was a trend toward improved fixation on microperimetry. Conclusion. Results of the study show that after 2RT therapy the condition of the retina can stabilize or even improve, supporting the broader use of retinal laser stimulation using a nanosecond laser in patients with early forms of AMD to prevent the progression of the disease and its transition to the wet form.
- Open Access
- 15 December 2024
- Published by ECO-Vector LLC in Russian Pediatric Ophthalmology
- Vol. 19 (4) , 191-199
Evaluation of visual performance depending on tolerability of optical correction
Accommodative asthenopia is common in myopic patients when permanent full correction is prescribed, since their accommodative system does not tolerate increased stress due to close work. AIM: To evaluate visual performance in myopic school children depending on tolerability of optical correction. MATERIAL AND METHODS: A total of 154 children (11 to 16 years) with different levels of myopia, wearing corrective spectacles. Of them, 56 and 98 school children had good and poor tolerability of optical correction according to computed accommodation test, respectively. Accommodation was measured using autorefractor Righton Speedy-K ver. MF-1. Visual performance was evaluated using Bourdon test. Performance accuracy (At), accuracy factor (Ta), productivity (Pt), endurance factor (Kp), and speed of information processing (S) were determined. RESULTS: In the group where spectacle correction caused asthenopia during visual tasking, performance accuracy, productivity, and accuracy factor exceeded the mean values in children without signs of accommodative asthenopia. But endurance factor and speed of information processing are significantly lower compared to the children with good tolerability of optical correction. CONCLUSION: Tolerability of optical correction affects visual performance of school children. Poor tolerability of optical correction significantly decreases visual performance parameters, such as performance accuracy, productivity, and endurance.
- 15 December 2024
- Published by ECO-Vector LLC in Russian Pediatric Ophthalmology
- Vol. 19 (4) , 191-199
Open AccessEvaluation of visual performance depending on tolerability of optical correction
Accommodative asthenopia is common in myopic patients when permanent full correction is prescribed, since their accommodative system does not tolerate increased stress due to close work. AIM: To evaluate visual performance in myopic school children depending on tolerability of optical correction. MATERIAL AND METHODS: A total of 154 children (11 to 16 years) with different levels of myopia, wearing corrective spectacles. Of them, 56 and 98 school children had good and poor tolerability of optical correction according to computed accommodation test, respectively. Accommodation was measured using autorefractor Righton Speedy-K ver. MF-1. Visual performance was evaluated using Bourdon test. Performance accuracy (At), accuracy factor (Ta), productivity (Pt), endurance factor (Kp), and speed of information processing (S) were determined. RESULTS: In the group where spectacle correction caused asthenopia during visual tasking, performance accuracy, productivity, and accuracy factor exceeded the mean values in children without signs of accommodative asthenopia. But endurance factor and speed of information processing are significantly lower compared to the children with good tolerability of optical correction. CONCLUSION: Tolerability of optical correction affects visual performance of school children. Poor tolerability of optical correction significantly decreases visual performance parameters, such as performance accuracy, productivity, and endurance.
- 23 April 2024
- Published by Media Sphere Publishing Group in Russian Annals of Ophthalmology
- Vol. 140 (6) , 100-106
Dual inhibition of VEGF-A and angiopoietin-2 in the treatment of neovascular age-related macular degeneration and diabetic macular edema
The introduction of faricimab, a drug targeting both vascular endothelial growth factor-A (VEGF-A) and angiopoietin-2, has enabled the implementation of the highly effective dual inhibition strategy in real clinical practice for patients with neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME), both previously treated with intravitreal injections and newly diagnosed. This article presents a series of 11 clinical cases involving patients with nAMD and DME who received loading doses of faricimab and continued ophthalmological observation. Among them, three patients with nAMD and two with DME were treatment-naïve, while the others were switched from alternative therapies to faricimab. The duration of follow-up after the loading phase ranged from 4 to 24 weeks at the time of this writing. All patients showed a pronounced anatomical improvement, and seven of the 11 experienced an increase in visual acuity. All reported subjective vision improvement, and no adverse events. These results confirm the high efficacy and safety of faricimab for nAMD and DME, both in treatment-naïve patients and those switched from other therapies.
- 23 April 2024
- Published by Media Sphere Publishing Group in Russian Annals of Ophthalmology
- Vol. 140 (6) , 100-106
Dual inhibition of VEGF-A and angiopoietin-2 in the treatment of neovascular age-related macular degeneration and diabetic macular edema
The introduction of faricimab, a drug targeting both vascular endothelial growth factor-A (VEGF-A) and angiopoietin-2, has enabled the implementation of the highly effective dual inhibition strategy in real clinical practice for patients with neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME), both previously treated with intravitreal injections and newly diagnosed. This article presents a series of 11 clinical cases involving patients with nAMD and DME who received loading doses of faricimab and continued ophthalmological observation. Among them, three patients with nAMD and two with DME were treatment-naïve, while the others were switched from alternative therapies to faricimab. The duration of follow-up after the loading phase ranged from 4 to 24 weeks at the time of this writing. All patients showed a pronounced anatomical improvement, and seven of the 11 experienced an increase in visual acuity. All reported subjective vision improvement, and no adverse events. These results confirm the high efficacy and safety of faricimab for nAMD and DME, both in treatment-naïve patients and those switched from other therapies.
- Open Access
- 22 March 2024
- Published by Real Time, Ltd. in Russian Ophthalmological Journal
- Vol. 17 (1) , 7-19
The compliance of specialized medical care of patients with glaucoma to clinical recommendations (CR 96/1 “Primary open-angle glaucoma”) in Russian Federation regions
The high prevalence of primary open-angle glaucoma, its leading role in the structure of visual disability, and insufficient effectiveness of treatment, prevention and rehabilitation measures require new approaches to providing quality care of patients with glaucoma. It is important to analyze the epidemiological situation, human and technological resources in various regions of the Russian Federation. The paper evaluates the compliance of specialized medical care of patients with glaucoma with the approved clinical guidelines CR 96 “Primary open-angle glaucoma” in the regions of the Russian Federation monitored by the Helmholtz National Research Center for Eye Diseases, based on the material of on-site data collection visits. The epidemiological situation relating to glaucoma, the structure and performance indicators of ophthalmological service departments, preventive measures, human and material resources, and the correctness of statistical accounting and reporting were studied. In most regions, the times of examination and treatment correspond to the regional territorial programs covered by state guarantees. The cases when primary specialized care lags behind is associated with staff shortage at the outpatient level. Practically in all regions of the Russian Federation, diagnostic methods and conservative/surgical treatment techniques with proven high efficiency conform to CR 96/1 “Primary open-angle glaucoma”. Some of the regions, however, are insufficiently equipped for early diagnosis of glaucoma and monitoring its course.
- 22 March 2024
- Published by Real Time, Ltd. in Russian Ophthalmological Journal
- Vol. 17 (1) , 7-19
Open AccessThe compliance of specialized medical care of patients with glaucoma to clinical recommendations (CR 96/1 “Primary open-angle glaucoma”) in Russian Federation regions
The high prevalence of primary open-angle glaucoma, its leading role in the structure of visual disability, and insufficient effectiveness of treatment, prevention and rehabilitation measures require new approaches to providing quality care of patients with glaucoma. It is important to analyze the epidemiological situation, human and technological resources in various regions of the Russian Federation. The paper evaluates the compliance of specialized medical care of patients with glaucoma with the approved clinical guidelines CR 96 “Primary open-angle glaucoma” in the regions of the Russian Federation monitored by the Helmholtz National Research Center for Eye Diseases, based on the material of on-site data collection visits. The epidemiological situation relating to glaucoma, the structure and performance indicators of ophthalmological service departments, preventive measures, human and material resources, and the correctness of statistical accounting and reporting were studied. In most regions, the times of examination and treatment correspond to the regional territorial programs covered by state guarantees. The cases when primary specialized care lags behind is associated with staff shortage at the outpatient level. Practically in all regions of the Russian Federation, diagnostic methods and conservative/surgical treatment techniques with proven high efficiency conform to CR 96/1 “Primary open-angle glaucoma”. Some of the regions, however, are insufficiently equipped for early diagnosis of glaucoma and monitoring its course.
- Open Access
- 9 December 2023
- Published by FSBEI of Higher Education SamSMU of Ministry of Health of the Russian Federation in Aspirantskiy Vestnik Povolzhiya
- Vol. 23 (4) , 44-50
Suprachoroidal administration of triamcinolone acetonide in patients with macular edema after vitrectomy: Technique and results
Aim – to study the effectiveness of triamcinolone acetonide (TA) injection into the suprachoroidal space using a microneedle for the treatment of macular edema after vitrectomy. Material and methods. During the study, the results of suprachoroidal administration of triamcinolone acetonide were analyzed in 8 patients (8 eyes) who were observed with macular edema as a complication of vitrectomy. Ophthalmological examination included visometry, non-contact tonometry, indirect ophthalmoscopy with lens 78 D, and optical coherence tomography (OCT) of the macular area. Best corrected visual acuity (BCVA) before the operation ranged from 0.1 to 0.8 (0.25 (0.10; 0.50), retinal thickness in the foveolar area varied from 342 to 728 µm (513.0 (443.0; 585.5) according to OCT data. During the operation, all patients underwent the injection of 0.1 ml of triamcinolone acetonide using a microneedle into the suprachoroidal space 3.5-4.0 mm posterior to the limbus. Results. One month after suprachoroidal injection of TA, the thickness of macular edema statistically significantly decreased to 327.5 (309.0; 380.5) μm (p = 0.011719) and BCVA increased to 0.45 (0.25; 0.80) (p = 0.027709). Three months after surgery, the retinal thickness in the macular area was 333.5 (311.5; 503.0) (p = 0.068704). The lack of statistical significance in the reduction of macular edema 3 months after suprachoroidal TA injection is explained by the fact that 3 out of 8 patients (37.5%) experienced a recurrence of macular edema after 3 months. However, BCVA has significantly increased to 0.6 (0.25; 0.90) (p = 0.043115). In 5 out of 8 patients (62.5%) a stable positive result was achieved within 3 months in the form of relief of macular edema. In the postoperative period, an increase in intraocular pressure was noted only in 2 cases of measurements, in patients observed for secondary glaucoma as a concomitant diagnosis. Intraocular pressure was compensated in both cases after correction of the treatment regimen. Conclusion. The presented technique is effective in treatment of macular edema associated with vitrectomy, as well as safe, which may be the reason for its further study.
- 9 December 2023
- Published by FSBEI of Higher Education SamSMU of Ministry of Health of the Russian Federation in Aspirantskiy Vestnik Povolzhiya
- Vol. 23 (4) , 44-50
Open AccessSuprachoroidal administration of triamcinolone acetonide in patients with macular edema after vitrectomy: Technique and results
Aim – to study the effectiveness of triamcinolone acetonide (TA) injection into the suprachoroidal space using a microneedle for the treatment of macular edema after vitrectomy. Material and methods. During the study, the results of suprachoroidal administration of triamcinolone acetonide were analyzed in 8 patients (8 eyes) who were observed with macular edema as a complication of vitrectomy. Ophthalmological examination included visometry, non-contact tonometry, indirect ophthalmoscopy with lens 78 D, and optical coherence tomography (OCT) of the macular area. Best corrected visual acuity (BCVA) before the operation ranged from 0.1 to 0.8 (0.25 (0.10; 0.50), retinal thickness in the foveolar area varied from 342 to 728 µm (513.0 (443.0; 585.5) according to OCT data. During the operation, all patients underwent the injection of 0.1 ml of triamcinolone acetonide using a microneedle into the suprachoroidal space 3.5-4.0 mm posterior to the limbus. Results. One month after suprachoroidal injection of TA, the thickness of macular edema statistically significantly decreased to 327.5 (309.0; 380.5) μm (p = 0.011719) and BCVA increased to 0.45 (0.25; 0.80) (p = 0.027709). Three months after surgery, the retinal thickness in the macular area was 333.5 (311.5; 503.0) (p = 0.068704). The lack of statistical significance in the reduction of macular edema 3 months after suprachoroidal TA injection is explained by the fact that 3 out of 8 patients (37.5%) experienced a recurrence of macular edema after 3 months. However, BCVA has significantly increased to 0.6 (0.25; 0.90) (p = 0.043115). In 5 out of 8 patients (62.5%) a stable positive result was achieved within 3 months in the form of relief of macular edema. In the postoperative period, an increase in intraocular pressure was noted only in 2 cases of measurements, in patients observed for secondary glaucoma as a concomitant diagnosis. Intraocular pressure was compensated in both cases after correction of the treatment regimen. Conclusion. The presented technique is effective in treatment of macular edema associated with vitrectomy, as well as safe, which may be the reason for its further study.
- Open Access
- 9 December 2023
- Published by FSBEI of Higher Education SamSMU of Ministry of Health of the Russian Federation in Aspirantskiy Vestnik Povolzhiya
- Vol. 23 (4) , 27-31
Micropulse cyclophoto-coagulation in patients with primary open-angle glaucoma: early results
Aim – to evaluate the efficacy and safety of micropulse transscleral cyclophotocoagulation (MP-TSCPC) procedure in patients with primary open-angle glaucoma (POAG). Material and methods. The study was conducted in 21 patients with POAG and uncompensated intraocular pressure (IOP) using pharmacotherapy. All patients underwent MP-TSCPC procedure with IRIDEX Cyclo G6 device. The follow-up period lasted for 1 month. During this time, the visual acuity, IOP dynamics, complications, as well as the number of hypotensive drugs used were evaluated. Statistical analysis was performed using STATISTICA 12.0 software. Results. Among patients with moderate and advanced glaucoma, the IOP reduced by 46.7 (3.3; 64.3) % from baseline values by the end of the follow-up period. The target IOP was achieved in 30.7% of patients. In 75% of patients who achieved target IOP, the number of hypotensive drops used was reduced by 1 component. In all patients with terminal stage glaucoma, pain was relieved, and IOP was reduced by 35.5 (8.4; 41.1) %. No intra- or postoperative complications were reported in any case. Conclusion. MP-TSCPC can be considered as a relatively safe adjunctive method to achieve target IOP in addition to medical treatment in patients with moderate and advanced glaucoma, as well as appropriate method to control pain in patients with the terminal stage of the disease.
- 9 December 2023
- Published by FSBEI of Higher Education SamSMU of Ministry of Health of the Russian Federation in Aspirantskiy Vestnik Povolzhiya
- Vol. 23 (4) , 27-31
Open AccessMicropulse cyclophoto-coagulation in patients with primary open-angle glaucoma: early results
Aim – to evaluate the efficacy and safety of micropulse transscleral cyclophotocoagulation (MP-TSCPC) procedure in patients with primary open-angle glaucoma (POAG). Material and methods. The study was conducted in 21 patients with POAG and uncompensated intraocular pressure (IOP) using pharmacotherapy. All patients underwent MP-TSCPC procedure with IRIDEX Cyclo G6 device. The follow-up period lasted for 1 month. During this time, the visual acuity, IOP dynamics, complications, as well as the number of hypotensive drugs used were evaluated. Statistical analysis was performed using STATISTICA 12.0 software. Results. Among patients with moderate and advanced glaucoma, the IOP reduced by 46.7 (3.3; 64.3) % from baseline values by the end of the follow-up period. The target IOP was achieved in 30.7% of patients. In 75% of patients who achieved target IOP, the number of hypotensive drops used was reduced by 1 component. In all patients with terminal stage glaucoma, pain was relieved, and IOP was reduced by 35.5 (8.4; 41.1) %. No intra- or postoperative complications were reported in any case. Conclusion. MP-TSCPC can be considered as a relatively safe adjunctive method to achieve target IOP in addition to medical treatment in patients with moderate and advanced glaucoma, as well as appropriate method to control pain in patients with the terminal stage of the disease.